drugset / Trial / NCT07407283
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
The study aims to assess the safety and tolerability of SHR-4394 in combination with anti-tumor therapy in participants with prostate cancer, and determine the recommended Phase II dose (RP2D); To evaluate of the efficacy of SHR-4394 in combination with anti-tumor therapy in participants with prostate cancer based on Prostate-Specific Antigen (PSA) response rate.
Timeline
- Start
- 2026-04-08
- Primary completion
- 2027-11
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR4394 | Unknown | — | — |
| Background | HRS-5041 | Other / unclassified | — | — |
| Background | Rezvilutamide | Small molecule | — | — |
| Background | Tazemetostat | Small molecule | — | — |